The clinical trial investigates the efficacy of Liraglutide, a GLP-1 receptor agonist, in preventing glucocorticoid-induced hyperglycemia in patients at high risk for diabetes. Given the increasing prevalence of diabetes and the common use of glucocorticoids in various therapeutic regimens, successful outcomes could position Liraglutide as a critical preventive therapy in this patient population. The market potential is significant, particularly as there are currently no approved preventive therapies for glucocorticoid-induced diabetes. Competitive analysis indicates that while other GLP-1 receptor agonists exist, Liraglutide's specific application in this context may provide a unique market niche. Diligence should focus on the trial's recruitment status and any potential regulatory hurdles.